PCG
66
5
AZO
50
2
YUM
43
3
PNW
57
4
STT
64
5
PFG
30
3
KO
46
4
GE
64
4
LNC
29
4
PG
43
2
PAYX
45
6
ADI
59
2
GT
47
4
CMG
64
3
COF
52
5
AON
30
2
PLD
40
2
VTR
46
3
CL
50
3
STX
37
2
PCG
66
5
AZO
50
2
YUM
43
3
PNW
57
4
STT
64
5
PFG
30
3
KO
46
4
GE
64
4
LNC
29
4
PG
43
2
PAYX
45
6
ADI
59
2
GT
47
4
CMG
64
3
COF
52
5
AON
30
2
PLD
40
2
VTR
46
3
CL
50
3
STX
37
2
Financhill
Back

Regeneron Pharmaceuticals 10K Form

Sell
45

REGN
Regeneron Pharmaceuticals

Last Price:
$713.28
Seasonality Move:
10.8%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-11-02 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-08-03 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-05-04 10Q REGN/Regeneron Pharmaceuticals Quarterly
2022-11-03 10Q REGN/Regeneron Pharmaceuticals Quarterly
2022-08-03 10Q REGN/Regeneron Pharmaceuticals Quarterly

Receive REGN News And Ratings

See the #1 stock for the next 7 days that we like better than REGN

REGN Financial Statistics

Sales & Book Value

Annual Sales: $13.1B
Cash Flow: $1B
Price / Cash Flow: 24.78
Annual Sales: $266.32
Price / Book: 2.68

Profitability

EPS (TTM): 40.41000
Net Income (TTM): $4.7B
Gross Margin: $11.3B
Return on Equity: 17.19%
Return on Assets: 13.44%

Regeneron Pharmaceuticals Earnings Forecast

Key Regeneron Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 34 years for REGN is 86.16%.
  • The Selling, General & Administrative Expenses for REGN have been equal to 20.06% of Gross Profit Margin.
  • The Research & Development expenses have been 33.84% of Revenue.
  • The Interest Expense is 1.85% of Operating Income.
  • The Net Earning history of REGN is 30.14% of Total Revenues.
  • Per Share Earnings over the last 34 years have been positive in 18 years.

Regeneron Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: S&P500
Industry: Biotechnology
Sector: Health Care
Current Symbol: REGN
CUSIP: 75886F
Website: regeneron.com

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 5.28
Quick Ratio: 4.34

Price-to-Earnings

Trailing P/E Ratio: 20.55
Forward P/E Ratio: 15.9

REGN Technical Analysis vs Fundamental Analysis

Sell
45
Regeneron Pharmaceuticals (REGN) is a Sell

Is Regeneron Pharmaceuticals a Buy or a Sell?